Anand Basi, MD
Internal Medicine · Cleveland, TXNPI 1639270291
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 336 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 336 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$935
- AstraZeneca$830
- Novo Nordisk$457
- Lilly USA, LLC$454
- AbbVie$321
- Mylan Specialty L.p.$267
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,710100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 55 | $935 |
| AstraZeneca | 40 | $830 |
| Novo Nordisk | 28 | $457 |
| Lilly USA, LLC | 32 | $454 |
| AbbVie(2 entities) | 19 | $321 |
| Mylan Specialty L.p. | 13 | $267 |
| Pfizer | 17 | $265 |
| Sunovion Pharmaceuticals Inc. | 21 | $232 |
| Amgen | 14 | $230 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $219 |
| Boehringer Ingelheim | 11 | $185 |
| Otsuka America Pharmaceutical, Inc. | 9 | $172 |
| Lundbeck LLC | 6 | $124 |
| Sanofi-aventis U.S. LLC | 7 | $107 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $103 |
| Xeris Pharmaceuticals, Inc. | 5 | $97 |
| Astellas Pharma US Inc | 5 | $92 |
| Johnson & Johnson(2 entities) | 5 | $71 |
| Abbott | 3 | $67 |
| Exact Sciences | 3 | $60 |
| Alnylam Pharmaceuticals Inc. | 2 | $49 |
| Edwards Lifesciences | 1 | $41 |
| Bayer | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $31 |
| Acadia Pharmaceuticals Inc | 2 | $30 |
| Genentech USA, Inc. | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Viatris Specialty LLC | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Novartis | 2 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Fidia Pharma USA Inc. | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Biogen | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Radius Health, Inc. | 1 | $12 |
How this compares
$5,716 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 194 | $225,081 |
| MounjaroTirzepatide | 121 | $137,183 |
| EliquisApixaban | 85 | $102,258 |
| FarxigaDapagliflozin Propanediol | 92 | $73,378 |
| JardianceEmpagliflozin | 66 | $68,891 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 55 | $42,388 |
| XareltoRivaroxaban | 45 | $41,838 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $40,633 |
| MyrbetriqMirabegron | 48 | $35,155 |
| JanuviaSitagliptin Phosphate | 24 | $21,833 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $21,374 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $15,446 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $14,560 |
| EntrestoSacubitril/Valsartan | 14 | $10,701 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $9,278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $457 | $225,081194 claims |
| Lilly USA, LLCMounjaro | $454 | $137,183121 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $830 | $120,641164 claims |
| PfizerEliquis | $265 | $102,25885 claims |
| Boehringer IngelheimJardiance | $185 | $68,89166 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $935 | $64,47192 claims |
| Johnson & JohnsonXarelto | $71 | $41,83845 claims |
| Astellas Pharma US IncMyrbetriq | $92 | $35,15548 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $107 | $18,16428 claims |
| NovartisEntresto | $25 | $10,70114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Cleveland
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.